inPractice® - HCV Treatment

Data show that HCV therapy with DAAs is highly effective and safe in persons with active or recent IDU and/or who are receiving OST, with SVR12 rates exceeding 90% in these populations^{[Feld 2014; Grebely 2017; Grebely 2016a; Grebely 2016b; Zeuzem 2015; Dore 2016; Foster 2017]}
Guidelines from both the AASLD and EASL recommend HCV treatment of PWID in conjunction with linkage to harm-reduction strategies^{[AASLD-IDSA HCV; EASL HCV]}
Some cases of HCV reinfection should be expected among PWID following HCV clearance due to ongoing risk behavior^{[Simmons 2016]}